Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6643050 | 0.90 | SMN1; SMN2 (0.63) | ALDH1A1SMN1; SMN2POLBL3MBTL1TSHR | |
| SCHEMBL6335581 | 0.89 | SMN1; SMN2 (0.66) | ALDH1A1SMN1; SMN2POLBL3MBTL1TSHR | |
| SCHEMBL11189770 | 0.88 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2POLBL3MBTL1TSHR | |
| SCHEMBL11786130 | 0.88 | SMN1; SMN2 (0.64) | ALDH1A1SMN1; SMN2POLBL3MBTL1TSHR | |
| SCHEMBL4461404 | 0.84 | SMN1; SMN2 (0.51) | ALDH1A1SMN1; SMN2POLBL3MBTL1TSHR | |
| SCHEMBL7321968 | 0.84 | TRPM8 (0.48) | ALDH1A1SMN1; SMN2POLBL3MBTL1TSHR | |
| SCHEMBL15864380 | 0.83 | NPC1 (0.49) | ALDH1A1SMN1; SMN2POLBL3MBTL1TSHR | |
| SCHEMBL27956363 | 0.83 | NPC1 (0.65) | ALDH1A1SMN1; SMN2POLBL3MBTL1TSHR | |
| SCHEMBL358221 | 0.83 | POLB (0.60) | ALDH1A1SMN1; SMN2POLBL3MBTL1TSHR | |
| Hydrochloric Acid SCHEMBL8763040 | 0.83 | SMN1; SMN2 (0.50) | ALDH1A1SMN1; SMN2POLBL3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110054186-A1 | PROCESS FOR EPROSARTAN INTERMEDIATE | HETERO RESEARCH FOUNDATION (IN) | 2011-03-03 | — | — | US | claimed |
| EP-2257540-A2 | IMPROVED PROCESS FOR EPROSARTAN INTERMEDIATE | Hetero Research Foundation (IN) | 2010-12-08 | — | — | EP | claimed |
| US-20100137613-A1 | PROCESS FOR EPROSARTAN | HETERO DRUGS LIMITED (IN) | 2010-06-03 | — | — | US | claimed |
| WO-2009122421-A2 | IMPROVED PROCESS FOR EPROSARTAN INTERMEDIATE | HETERO RESEARCH FOUNDATION (IN) | 2009-10-08 | — | — | WO | claimed |
| EP-2097408-A1 | IMPROVED PROCESS FOR EPROSARTAN | Hetero Drugs Limited (IN) | 2009-09-09 | — | — | EP | claimed |
| WO-2008078330-A1 | IMPROVED PROCESS FOR EPROSARTAN | HETERO DRUGS LIMITED (IN) | 2008-07-03 | — | — | WO | claimed |
| US-9884836-B2 | 2-substituted-5-hydroxy-4H-chromen-4-ones as novel ligands for the serotonin receptor 2B (5-HT2B) | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2018-02-06 | — | — | US | disclosed |
| US-20170029399-A1 | 2-SUBSTITUTED-5-HYDROXY-4H-CHROMEN-4-ONES AS NOVEL LIGANDS FOR THE SEROTONIN RECEPTOR 2B (5-HT2B) | VIRGINIA COMMONWEALTH UNIVERSITY | 2017-02-02 | — | — | US | disclosed |
| WO-2015116460-A1 | 2-SUBSTITUTED-5-HYDROXY-4H-CHROMEN-4-ONES AS NOVEL LIGANDS FOR THE SEROTONIN RECEPTOR 2B (5-HT2B) | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2015-08-06 | — | — | WO | disclosed |
| WO-2014106763-A1 | PYRIDOPYRAZINES AS ANTICANCER AGENTS | VICHEM CHEMIE KUTATÓ KFT. (HU) | 2014-07-10 | — | — | WO | disclosed |
| WO-2014106763-A1 | PYRIDOPYRAZINES AS ANTICANCER AGENTS | VICHEM CHEMIE KUTATÓ KFT. (HU) | 2014-07-10 | — | — | WO | disclosed |
| US-8361507-B2 | Eprosartan mesylate crystalline particles and a process for preparing pure eprosartan | HETERO DRUGS LIMITED (IN) | 2013-01-29 | — | — | US | disclosed |
| WO-2009122421-A3 | IMPROVED PROCESS FOR EPROSARTAN INTERMEDIATE | HETERO RESEARCH FOUNDATION (IN) | 2011-05-26 | — | — | WO | disclosed |
| US-5312828-A | Substituted imidazoles having angiotensin II receptor blocking activity | SMITHKLINE BEECHAM CORPORATION A CORP. OF PENNSYLVANIA | 1994-05-17 | — | — | US | disclosed |
| CN-1079649-A | Preparation contains the method for the pharmaceutical composition of imidazolyl-alkenoic acids | SMITHKLINE BEECHAM CORP (US) | 1993-12-22 | — | — | CN | disclosed |
| US-5185351-A | Hypotensive agents; for treatment of congestive heart failure, renal failure and glaucoma | SMITHKLINE BEECHAM CORPORATION (US) | 1993-02-09 | — | — | US | disclosed |
| CN-1048038-A | IMIDAZOLYL-ALKENOIC ACIDS | SMITHKLINE BEECHAM CORP (US) | 1990-12-26 | — | — | CN | disclosed |
| EP-0403158-A2 | Imidazolyl-alkenoic acids | SMITHKLINE BEECHAM CORPORATION (US) | 1990-12-19 | — | — | EP | disclosed |
| US-4216318-A | HISTAMINE HZ-ANTAGONISTS, ISOCYTOSINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-08-05 | — | — | US | disclosed |
| US-4154834-A | HETEROCYCLIC-(THIO)ALKYLAMINO SUBSTITUTED-4-PYRIMIDONE OR -THIONES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110054186-A1 | PROCESS FOR EPROSARTAN INTERMEDIATE | PTGER1, PTGER4, PDGFRA | ALDH1A1 761/4885SMN1; SMN2 2663/4885POLB 1787/4885 |
| US-20100137613-A1 | PROCESS FOR EPROSARTAN | PTMA, PTGER1, PDGFRA | ALDH1A1 732/4885SMN1; SMN2 1398/4885POLB 1208/4885 |
| US-20170029399-A1 | 2-SUBSTITUTED-5-HYDROXY-4H-CHROMEN-4-ONES AS NOVEL LIGANDS FOR THE SEROTONIN RECEPTOR 2B (5-HT2B) | HTR2B, HTR3B, HTR4 | ALDH1A1 2542/4885SMN1; SMN2 1947/4885POLB 3947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.